Neil F. McFarlane, President and Chief Executive Officer of Zevra Therapeutics (NASDAQ: ZVRA), reported an insider sale and related equity transactions in recent filings with the U.S. Securities and Exchange Commission.
According to a Form 4 filing, McFarlane sold 91,000 shares of Zevra common stock on February 2, 2026, generating proceeds of approximately $853,425. The trades executed at a weighted average price of $9.3783 per share, with individual transaction prices reported between $8.94 and $9.53.
The filing also discloses that McFarlane exercised options to acquire 233,334 shares of Zevra Therapeutics common stock on January 31, 2026. In addition to the exercise, McFarlane received equity awards at the end of January: 125,000 restricted stock units and 250,000 stock options were granted to him on January 29, 2026, as recorded in the corporate disclosures.
These insider transactions come amid the company’s recent quarterly reporting and a distribution agreement announcement. For the third quarter of 2025, Zevra Therapeutics reported earnings per share of -$0.01, which exceeded the consensus estimate of -$0.03. Revenues for the quarter totaled $26.1 million, narrowly missing the expected $26.64 million.
Separately, Zevra announced an exclusive expanded access distribution agreement with Uniphar that broadens the territories covered by its Miplyffa (arimoclomol) program, intended for patients with Niemann-Pick Disease Type C. Following the agreement, H.C. Wainwright reiterated its Buy rating on Zevra and maintained a $26.00 price target.
The company’s filings and public disclosures collectively document a sequence of equity-related moves by the CEO together with recent operational and commercial developments. The reported sale, option exercises, and awards are reflected in the SEC filing record, while the quarterly results and the Uniphar distribution arrangement are described in the company’s public financial and corporate communications.
Additional context provided in filings and reports:
- Sale executed on February 2, 2026: 91,000 shares sold for approximately $853,425 at a weighted average price of $9.3783 (price range $8.94 to $9.53).
- Option exercise on January 31, 2026: 233,334 shares acquired through exercised options.
- Equity awards on January 29, 2026: 125,000 restricted stock units and 250,000 stock options granted.
Readers should note that the information above is taken from the company’s filings and public statements; the report presents those items without inference beyond the stated facts.